Alerts will be sent to your verified email
Verify Email
ZIMLAB
|
Zim Laboratories
|
Lyka Labs
|
Trident Lifeline
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
11.0 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
7.41 % | 62.44 % | 35.94 % |
|
5yr average Equity Multiplier
|
1.88 | 2.9 | 1.91 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.73 | 0.9 |
|
5yr Avg Net Profit Margin
|
4.15 % | -0.79 % | 17.11 % |
|
Price to Book
|
1.46 | 3.45 | 5.84 |
|
P/E
|
39.27 | 47.57 | 28.62 |
|
5yr Avg Cash Conversion Cycle
|
37.07 Days | 32.55 Days | 94.4 Days |
|
Inventory Days
|
68.72 Days | 24.2 Days | 68.55 Days |
|
Days Receivable
|
99.71 Days | 92.33 Days | 104.41 Days |
|
Days Payable
|
143.26 Days | 106.74 Days | 126.58 Days |
|
5yr Average Interest Coverage Ratio
|
3.96 | 2.2 | 17.94 |
|
5yr Avg ROCE
|
13.52 % | 25.83 % | 29.15 % |
|
5yr Avg Operating Profit Margin
|
12.21 % | 24.02 % | 16.89 % |
|
5 yr average Debt to Equity
|
0.39 | 1.25 | 0.34 |
|
5yr CAGR Net Profit
|
10.7 % | n/a | 9.93 % |
|
5yr Average Return on Assets
|
4.02 % | 1.72 % | 15.87 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
33.26 % | 58.16 % | 63.04 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 3.46 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 10.36 % | -6.53 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | -3.53 % | 0.0 |
|
Zim Laboratories
|
Lyka Labs
|
Trident Lifeline
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Capex
|
Capex
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|